The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial
| Autor: | Jack A. Sargeant, James A. King, Thomas Yates, Emma L. Redman, Danielle H. Bodicoat, Sudesna Chatterjee, Charlotte L. Edwardson, Laura J. Gray, Benoit Poulin, Ghazala Waheed, Helen L. Waller, David R. Webb, Scott A. Willis, John P. H. Wilding, Kamlesh Khunti, David J. Stensel, Melanie J. Davies |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Adult
Endocrinology Diabetes and Metabolism Appetite Middle Aged Overweight Ghrelin Endocrinology Glucose Diabetes Mellitus Type 2 Double-Blind Method Glucosides Glucagon-Like Peptide 1 Weight Loss Internal Medicine Humans Hypoglycemic Agents Peptide YY Obesity Benzhydryl Compounds Sodium-Glucose Transporter 2 Inhibitors Aged |
| Zdroj: | DIABETES OBESITY & METABOLISM |
| ISSN: | 1463-1326 |
| Popis: | To assess the impact of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin (25 mg once-daily), dietary energy restriction, or both combined, on circulating appetite-regulatory peptides in people with type 2 diabetes (T2D) and overweight or obesity.In a double-blind, placebo-controlled trial, 68 adults (aged 30-75 years) with T2D (drug naïve or on metformin monotherapy; HbA1c 6.0%-10.0% [42-86 mmol/mol]) and body mass index of 25 kg/mThe mean weight loss in each group at 24 weeks was 0.44, 1.91, 2.22 and 5.74 kg, respectively. The change from baseline to 24 weeks in postprandial total PYY was similar between experimental groups and placebo only (mean difference [95% CI]: -8.6 [-28.6 to 11.4], 13.4 [-6.1 to 33.0] and 1.0 [-18.0 to 19.9] pg/ml in placebo-plus diet, empagliflozin-only and empagliflozin-plus-diet groups, respectively [all P ≥ .18]). Similarly, there was no consistent pattern of difference between groups for postprandial total GLP-1, acylated ghrelin and subjective appetite perceptions.In people with T2D and overweight or obesity, changes in postprandial appetite-regulatory gut peptides may not underpin the less than predicted weight loss observed with empagliflozin therapy.NCT02798744, www.gov; 2015-001594-40, www.EudraCT.ema.europa.eu; ISRCTN82062639, www.ISRCTN.org. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text